Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 3.7%

Structure Therapeutics Inc. (NASDAQ:GPCR) traded down 3.7% on Monday . The stock traded as low as $35.35 and last traded at $35.59. 396,054 shares changed hands during trading, a decline of 50% from the average session volume of 784,280 shares. The stock had previously closed at $36.95.

Wall Street Analyst Weigh In

GPCR has been the subject of a number of recent research reports. JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research note on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price objective on the stock. BMO Capital Markets increased their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $84.63.

Structure Therapeutics Price Performance

The firm’s 50 day moving average is $37.96 and its 200 day moving average is $39.72. The company has a market cap of $1.85 billion, a PE ratio of -47.51 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its position in shares of Structure Therapeutics by 4.5% during the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after buying an additional 617 shares in the last quarter. Sandia Investment Management LP bought a new stake in Structure Therapeutics during the second quarter worth about $39,000. Brandywine Managers LLC boosted its holdings in shares of Structure Therapeutics by 9.2% in the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after purchasing an additional 1,007 shares in the last quarter. Quarry LP bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at about $79,000. Finally, Teachers Retirement System of The State of Kentucky increased its position in shares of Structure Therapeutics by 17.8% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after purchasing an additional 2,077 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.